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Abstract
Background: In higher primates, during non-pregnant cycles, it is indisputable that circulating LH is essential for
maintenance of corpus luteum (CL) function. On the other hand, during pregnancy, CL function gets rescued by
the LH analogue, chorionic gonadotropin (CG). The molecular mechanisms involved in the control of luteal
function during spontaneous luteolysis and rescue processes are not completely understood. Emerging evidence
suggests that LH/CGR activation triggers proliferation and transformation of target cells by various signaling
molecules as evident from studies demonstrating participation of Src family of tyrosine kinases (SFKs) and MAP
kinases in hCG-mediated actions in Leydig cells. Since circulating LH concentration does not vary during luteal
regression, it was hypothesized that decreased responsiveness of luteal cells to LH might occur due to changes in
LH/CGR expression dynamics, modulation of SFKs or interference with steroid biosynthesis.
Methods: Since, maintenance of structure and function of CL is dependent on the presence of functional LH/CGR
its expression dynamics as well as mRNA and protein expressions of SFKs were determined throughout the luteal
phase. Employing well characterized luteolysis and CL rescue animal models, activities of SFKs, cAMP
phosphodiesterase (cAMP-PDE) and expression of SR-B1 (a membrane receptor associated with trafficking of
cholesterol ester) were examined. Also, studies were carried out to investigate the mechanisms responsible for
decline in progesterone biosynthesis in CL during the latter part of the non-pregnant cycle.
Results and discussion: The decreased responsiveness of CL to LH during late luteal phase could not be
accounted for by changes in LH/CGR mRNA levels, its transcript variants or protein. Results obtained employing
model systems depicting different functional states of CL revealed increased activity of SFKs [pSrc (Y-416)] and PDE
as well as decreased expression of SR-B1correlating with initiation of spontaneous luteolysis. However, CG, by virtue
of its heroic efforts, perhaps by inhibition of SFKs and PDE activation, prevents CL from undergoing regression
during pregnancy.
Conclusions: The results indicated participation of activated Src and increased activity of cAMP-PDE in the control
of luteal function in vivo. That the exogenous hCG treatment caused decreased activation of Src and cAMP-PDE
activity with increased circulating progesterone might explain the transient CL rescue that occurs during early
pregnancy.
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The primary function of corpus luteum (CL) is to
secrete progesterone (P4), essential for establishment
and/or maintenance of pregnancy in mammals [1,2].
The structure and function of CL are controlled by
luteotrophic factors (stimulate growth and function) and
luteolytic factors (cause functional and structural regres-
sion). It is increasingly becoming apparent that there
exists a large diversity in the regulation of CL function
not only among species, but also within species at differ-
ent stages of the luteal phase dictated largely by the
intricate interplay between luteotrophic and luteolytic
factors. In higher primates, one of the important charac-
teristics of the regulation of CL function is that unlike
other species, circulating LH appears to be the sole
trophic factor responsible for its control during the
non-fertile cycle [3]. Intriguingly, circulating P4 levels
decline and the CL eventually undergoes regression at
the end of non-fertile cycle despite the accompanying
lack of decrease in LH levels [4,5]. On the other hand,
during pregnancy the increasing production of chorionic
gonadotropin (CG) elaborated by the placenta arrests
t h ed e c l i n ei nP 4 secretion resulting in rescue of CL
function [6]. Although recent studies continue to
expand our current understanding of the cellular and
molecular actions of LH/CG, knowledge of the pro-
cesses whereby LH/CG promote development and main-
tenance of CL function is far from clear. Though LH
and CG bind to a common LH/CG receptor (R), they
activate different signal transduction pathways for main-
tenance of CL function as reported in spheroidal cell
culture system of human granulosa lutein cells [7,8].
The LH/CGR is a G protein-coupled receptor (GPCR)
involving activation of Gs, Gi/o and Gq/11 family of G
proteins [9-12], but it is generally accepted that modula-
tion of Leydig/luteal cell function is mediated primarily
by the activation of the canonical Gs/cAMP/PKA/CREB
pathway [13,14]. Analysis of cAMP/PKA/CREB and
MAP kinase pathways in the luteal tissue has suggested
fine tuning of luteal function during luteolysis and res-
cue of CL function, however, involvement of these path-
ways alone does not appear to fully account for the
regulation of CL function [15]. Recently, several studies
have described the phenomenon of activated GPCRs to
crosstalk with or transactivate tyrosine kinase receptor
signaling [16,17], and extensive studies in mouse Leydig
tumor cells have demonstrated involvement of Src
family of kinases (SFKs) in modulation of LH/CG
responsiveness, and thereby regulation of Leydig cell
function [18-21]. Eventhough the precise mechanism by
which LH/CGR signaling causes activation of these
kinases and the functional consequences of their activa-
tion remains to be determined, SFKs might have an
important role in the regulation of CL function, perhaps
by modulation of LH/CG responsiveness, particularly
during the late luteal phase of non-fertile cycles. Thus,
studies are essential to identify other signaling pathways
to further delineate intraluteal processes to discern
those that are critical to the control of luteal function
and its life span.
To maintain high circulating P4 levels, steroid bio-
synthesis in luteal cells requires a constant supply of
cholesterol [22]. The intracellular cholesterol trafficking
from outer to inner mitochondrial membrane, regulated
by StAR protein, has been extensively investigated
[23,24]. On the other hand, the importance of choles-
terol acquisition into luteal cell needs to be explored to
further understand the process of substrate mobilization
to the CL. It has been suggested that cholesterol is pre-
ferentially sourced from circulating high- and low- den-
sity lipoproteins (HDL and LDL) [25,26]. Unlike the
classical LDL receptor pathway in which the entire lipo-
protein is internalized, the trafficking of cholesterol
from HDL involves binding of HDL-cholesteryl ester to
scavenger receptor class B type 1 (SR-B1) located on the
luteal cell, and only cholesteryl ester is delivered without
the concomitant uptake and degradation of the entire
HDL particle, leaving the lipoprotein at the cell surface
[27-31]. The expression changes of SR-B1 and its tran-
scriptional regulation by factors such as Liver receptor
homologue 1 (LRH-1/NR5A2) and Steroidogenic factor
1 (SF-1/NR5A1) become crucial to understanding the
regulation of CL function [32,33].
To further expand the knowledge on the regulation of
CL function during spontaneous luteolysis in monkeys,
studies have been carried out with following objectives:
to (i) establish correlation between circulating P4 and
the LH/CGR expression dynamics throughout the luteal
phase (ii) determine the expression and activation of Src
family of non-receptor tyrosine kinases and cAMP-phos-
phodiesterase (PDE), and (iii) to examine expression
patterns of SR-B1 and genes associated with steroido-
genesis in the CL.
Methods
Reagents
Trizol reagent and GenElute™ Gel Extraction Kit were
purchased from Sigma-Aldrich Co., (St Louis, MO,
USA). Oligonucleotide primers were synthesized by
Sigma-Genosys (Bangalore, India). Gonadotropin releas-
ing hormone receptor (GnRH/R) antagonist, Cetrorelix
®
( C E T )w a sak i n dg i f tf r o mA s t aM e d i c a( F r a n k f u r t ,
Germany). Recombinant human LH (rhLH) and hCG
(Profasi
®) were from Ares-Serono (Aubonne, Switzer-
land). Labelled a-
32P dCTP (LCP103) was from BRIT
(Hyd., India) and Random Primer extension Labeling Kit
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Polyclonal antibodies specific to LH/CGR (H-50: sc-
25828), PDE4D (H-69: sc-25814) and ERK-2 (# sc-154)
were from Santa Cruz Biotechnology Inc. (Santa Cruz
city, CA, USA). Phospho-Src family (Y-416; #2101), Src
Antibody sampler kit (#9935), p42/44 MAPK (# 9102),
Horse radish peroxidase labeled goat anti-rabbit IgG
and ECL chemiluminescence kit were from Cell Signal-
ing Technology (Beverly, MA, USA). Polyclonal antibody
against SR-B1 was a kind gift from Professor Salman
Azhar (Stanford University School of Medicine). Snake
venom nucleotidase (Crotalus atrox venom) was pro-
cured from Enzo Life Sciences, UK. Nylon and PVDF
membranes were purchased from NEN life Sciences,
(Boston, MA, USA). All other reagents were from
Sigma-Aldrich Co., (Bangalore, India) or sourced from
local distributors.
Animal protocols, blood samples, and CL collection
Experimental protocols in the monkeys described here
were approved by the Institutional Animal Ethics Com-
mittee of the Indian Institute of Science. The general
care and housing of monkeys at the Primate Research
Laboratory, Indian Institute of Science, Bangalore, have
been described elsewhere [13]. Adult female bonnet
monkeys (Macaca radiata)w e i g h i n g3 . 3t o5 . 1k gw i t ha
history of regular menstrual cyclicity (27-29 days) were
utilized for the study. Monkeys were monitored daily for
the onset of menses, and blood samples through femoral
venipuncture were collected daily from day 8-12 of the
menstrual cycle for determining the day of onset of E2
surge. Further, blood samples were collected either daily
or at more frequent intervals until the time of CL retrie-
val or onset of menses. In this study, one day after the
occurrence of E2 peak was designated as day 1 of the
luteal phase. The CL tissues on the designated day of the
luteal phase or at the end of treatment protocol (see
below) were retrieved from the ketamine hydrochloride
15 mg/kg BW and/or pentobarbital sodium (8 mg/kg
BW) anesthetized monkeys subjected to laparotomy
under aseptic conditions. The CL retrieved was trans-
ferred to a sterile petri dish containing filter paper, cut
into four or more pieces, a single piece each processed
for cAMP and PDE assays. The remaining pieces were
placed in individual sterile cryovials and snap frozen in
liquid nitrogen before storing at -70°C.
Experiment 1: Expression of LH/CGR, genes belonging to
SFKs, cAMP-PDE and SR-B1 in the monkey CL throughout
the luteal phase
CL tissues (n = 3/stage) were collected from monkeys
on day 5 [early (E)], day 8 [mid (M)], and on day 14
[late (L)] of the luteal phase as described previously
[15,34]. In addition, CL tissues (n = 3) were collected
from monkeys on day 1 of menses (D1M), a time point
when luteolytic events are considered to be manifest.
Blood samples were collected on designated days, to
determine the steroidogenic status of CL. The tissues
retrieved during different developmental stages were
used to examine the expression of genes considered
important for the modulation of the molecular events
that regulate CL structure and function during the luteal
phase.
Experiment 2: Effect of PGF2a treatment on expression of
LH/CGR, genes belonging to SFKs and SR-B1 in the
monkey CL
PGF2a treatment induces luteolysis in various species
without affecting the circulating LH levels [35]. An
experimental regimen has been standardized in the
laboratory in which three injections of Iliren, a synthetic
analogue of PGF2a (59 μg/kgBW) were administered at
8 h intervals on day 10 of the luteal phase and CL tis-
sues (n = 3) were collected 24 h after initiation of treat-
ment [34]. Similarly, on a separate occasion, the same
monkeys received three injections of PBS at 8 h intervals
beginning on day 10 of the luteal phase and CL tissues
were collected 24 h later to serve as control (VEH).
Blood samples were collected at different intervals
before and after treatment. The effect of PGF2a on
expression of various genes was examined.
Experiment 3: Expression and regulation of LH/CGR,
genes belonging to SFKs and SR-B1 in the monkey CL
during induced luteolysis (LH secretion inhibition) and
rescue of CL function (LH replacement)
To induce luteolysis, monkeys were administered with
GnRH-R antagonist, CET at a dose of 150 μg/kgBW s.c.,
on day 7 of the luteal phase, similarly on separate occa-
sions, the same monkeys received vehicle (5.25% glu-
cose; VEH) and CL tissues were collected 24 h after
CET/VEH treatment. Further, on day 8 of the luteal
phase, six monkeys treated with CET for 24 h were
further treated with either PBS (VEH, n = 3 monkeys)
or rhLH 20 IU/kgBW (rhLH, n = 3) i.v., and CL tissues
were collected at the end of 1 and 8 h rhLH treatment
[34]. Blood samples were collected at various time
points before and after treatment/s essentially as per the
earlier reported protocol [34]. The tissues obtained after
LH secretion inhibition and rescue of CL function by
LH replacement were subjected to examination of var-
ious genes, SFKs activation and cAMP levels.
Experiment 4: Expression and regulation of LH/CGR,
genes belonging to SFKs and SR-B1 in CL during
simulated early pregnancy
It is established that events associated with rescue of CL
function that occur during early pregnancy could be
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incremental doses of hCG [5]. To examine the expres-
sion of LH/CGR, genes belonging to SFKs and SR-B1
during simulated early pregnancy, monkeys were admi-
nistered hCG in incremental doses from day 9-13 of the
luteal phase (15, 30, 45, 90, and 180 IU, twice daily, i.
m.) and CL tissues were retrieved on d 14 of the luteal
phase as per the protocol previously reported [5]. For
comparison, CL collected on day 14 (late CL-L) of the
luteal phase but without hCG treatment, was used as
the control.
Hormone assays
Serum P4 concentrations were determined by specific
RIAs as reported previously [36]. The sensitivity of P4
assay was 0.1 ng/ml, and the inter- and intra-assay var-
iations were < 10%.
Preparation of CL tissue samples for cAMP assay
Fresh CL tissues collected from different experiments
were boiled immediately in boiling water (95°C) bath for
10 min to inactivate the PDE enzyme and then homoge-
nized in sterile H2O and centrifuged at 30,000 × g for
15 min. The supernatants were assayed for cAMP and
to increase the sensitivity of the assay, samples were
acetylated i.e., 100 μl of supernatant was made up to 1.5
ml final volume using 1X PBS, 30 μlo ft r i e t h y l a m i n e
and 15 μl of acetic anhydride and mixed properly for
acetylation process to complete. These acetylated sam-
ples were used for cAMP RIA.
Radioimmunoassay for cAMP
The assay procedure was standardized in the laboratory
as per the protocol of National Hormone & Peptide
Program (NHPP) and Steiner et.al., 1969 [37] The sensi-
tivity for cAMP assay was ~0.01 pmoles/tube and the
inter- and intra-assay variations were 5.2% and 7.4%
respectively. The antibody (CV-27) was used at the final
assay tube dilution of 1: 200,000 in a total assay set up
volume of 500 μl. The standard graph constructed with
concentrations of different acetylated standard on X-axis
and % binding on Y-axis was used to extrapolate con-
centration of cAMP in samples.
Determination of PDE activity using
3HcAMP as substrate
The cAMP-PDE activity assay was carried out as
reported previously with few modifications [38]. Fresh
CL tissues (8-10 mg) were homogenized in 200 μlo f
PDE lysis buffer and the lysate containing enzyme was
incubated with cocktail containing
3HcAMP substrate,
50 mM HEPES (pH 7.4) and 10 mM MgCl2 at 30°C
for 15 min. The PDE reaction was stopped by incubat-
ing the tubes in 95°C hot water bath for 3 min and
incubated again at 30°C for 15 min. To the reaction
mixture, 10 μl (50 KU) of snake venom nucleotidase
was added and incubated at 30°C for further 45 min.
The reaction mixture was applied on to 1 ml syringe
columns containing anion-exchange resin QAE sepha-
dex A-25 (200-400 mesh, GE life sciences, NJ, USA)
and equilibrated in 20 mM ammonium formate at pH
6.0 prior to use. The elution was carried out with 500
μl of 10 mM Tris pH 7.4, and the same was repeated
for further 5 more times. The eluant was mixed with
10 ml of scintillation fluid and the dpm in each sam-
ple was counted for 5 min in liquid scintillation
counter.
RNA isolation
Total RNA was isolated from CL tissues harvested from
different experiments using TRI Reagent according to
manufacturer’s instructions. RNA quantitation was per-
formed using NanoDrop ND-1000 UV-VIS spectrophot-
ometer (NanoDrop Products, Wilmington, DE) and
RNA samples with A260/A280 values of ~1.8-1.9 were
considered for further analysis.
Semi-quantitative RT-PCR analysis
Semi-quantitative RT-PCR analysis was carried out
essentially as described previously [39]. The details of
primers employed along with the annealing temperature
and expected amplicon size are provided in Additional
file 1: Table S1.
Real-time quantitative RT-PCR analysis
Real-time quantitative RT-PCR (qPCR) analysis was car-
ried out essentially as described previously [34]. Expres-
sion of L19 was used as internal control for
normalization of each gene examined. The list of genes
with details of the primers employed along with the
annealing temperature and expected amplicon size are
provided in Additional file 2: Table S2.
Northern blot analysis
Northern blot analysis was carried out as described pre-
viously with few modifications [40]. Briefly, total RNA
(15 μg) extracted from CL were electrophoresed and
blotted onto nylon membrane by capillary blotting for
16 h in 20× SSC. The blot was pre-hybridized for 2 h
and hybridized with a
32P-dCTP labeled LH/CGR cDNA
probe for 18 h at 65°C in Church buffer [41]. The blots
were then washed sequentially with buffers containing
varying concentrations of SSC + SDS and then pro-
cessed for autoradiography with an intensifying screen.
Hybridization signals were quantitated using a Phos-
phorImager (Typhoon 9210, Amersham biosciences).
The equal loading of RNA samples was confirmed by
reprobing the stripped blot with L-19 labelled cDNA
probe.
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CL tissue lysate preparation and immunoblot analysis
were carried out following the previously published pro-
cedures with some modifications [40]. Briefly, nonspeci-
fic sites on the membrane were blocked using 10% milk
in TBST by incubating 1 h at room temperature instead
of overnight at 4°C. Membrane was further incubated
with primary antibody specific for different proteins for
overnight at 4°C instead for 3 h at room temperature.
The membranes were developed by ECL chemilumines-
cence kit from Cell Signaling Technology (Beverly, MA)
instead of (NEN Life Sciences). Autoradiographs were
scanned using HP scanner or Syngene gel documenta-
tion system and quantitated by densitometry using Gene
tools software (Syngene laboratories, MD, USA) instead
of UVI-Tech gel documentation system and quantitated
using UVI-Band Map (1999) software.
Statistical analyses
Data were expressed as mean ± SEM. Statistical evalua-
tion of mean differences in P4 concentrations and qPCR
expression of genes was analysed by one-way ANOVA,
followed by the Newman- Keuls multiple comparison
test (PRISM GraphPad, version 5.0; GraphPad Software
Inc., San Diego, CA) and Student’s t-test to compare
between two groups. A p value of < 0.05 was considered
statistically significant.
Results
Expression and characterization of LH/CGR transcript
variants and protein in the monkey CL throughout the
luteal phase
Circulating mean serum P4 levels increased from early
to mid stage luteal phase (1.5 ± 0.2 vs. 3.4 ± 0.3 ng/ml),
however, P4 levels were low at the late luteal phase (1.4
± 0.1 ng/ml) and were 0.12 ± 0.01 ng/ml on day 1 of
menses (Figure 1A). The qPCR analysis of LH/CGR
expression at different stages of luteal phase revealed
that the mRNA expression increased progressively to
reach maximum at the late stage CL (2.4 ± 0.4, 3.3 ±
0.5 and 6.9 ± 1.2 ng/ml at early, mid and late stage,
respectively Figure 1A). Surprisingly, detectable expres-
sion of LH/CGR mRNA was observed in CL collected
on day 1 of menses (Figure 1A).
Northern blot analysis was performed for LH/CGR
mRNA to examine the presence of different transcripts
and their size in the monkey CL throughout the luteal
phase. As seen in Figure 1B, the alternative splicing for
LH/CGR mRNA was operational in the monkey CL and
four transcripts were detected, one major band with an
apparent size of 4.0 kb and three minor bands with
sizes of 1.0, 7.5 and 8.0 kb. All the four transcripts were
present in the CL tissues collected from monkeys at the
late luteal phase and on day 1 of menses, but the
intensity of transcripts was lower compared to mid
stage (Figure 1B). Since LH/CGR mRNA expression was
maximal at late luteal phase, it became of interest to
examine whether any of these transcript variants were
differentially regulated. The results indicated presence of
similar expression of splice variants both during mid
and late stage of the luteal phase (Figure 1B).
In contrast to the earlier report suggesting the absence
of LH/CGR mRNA expression in the regressing monkey
CL [42], in the present study the presence of LH/CGR
mRNA expression in the regressing CL prompted us to
employ multiple primer pairs PCR approach to further
determine the nature of alternative splicing variants. The
organization of LH/CGR gene and design of multiple pri-
mer pair sets and various predicted transcript variants
lacking different exons are provided in Additional file 3:
Figure S1. The sets of multiple primer pairs were designed
such that both full length transcripts and splice variants
would be detected. The details of primer sets, RT-PCR
conditions and the expected size of splice variants are
described in the Additional file 1: Table S1. Semi-quantita-
tive RT-PCR analysis of LH/CGR mRNA demonstrates
presence of two products of sizes 519 bp and 333 bp using
exon 7-11(F1-R1) primer set whereas, products of sizes
718 bp and 532 bp using exon 5-11(F2-R2) primer set cor-
responding to a full length transcript and one splice var-
iant lacking some exon region using both the primer sets
(Figure 1C). The four cDNA products [upper (519/718 bp)
and lower (333/532 bp) band using both the primer sets]
were gel eluted and sequenced. The nucleotide sequences
were compared with Gen Bank database using sequence
alignment at BLAST (Basic Local Alignment Search Tool)
and CLUSTALW tools from DNA Data Bank of Japan
(DDBJ)[43], National Center for Biological Information
(NCBI)[44] and GenomeNet [45] analysis showed ≥95%
sequence identity to human LH/CGR and ≥99% sequence
identity to monkey LH/CGR (Additional file 4: Figure S2A
and B). The two bands i.e., the upper band corresponding
to full length (519/718 bp) transcript and the lower band
(333/532 bp) corresponding to splice variant lacking exon
9 were detected throughout the luteal phase (Figure 1C).
The role of the splice variant lacking exon 9 is unclear
as while it is observed in the human ovary and binds
both LH and hCG in transfected in COS-1 cells, it
could not stimulate adenylate cyclase [46]. Further, it
was reported that this splice variant interacted with
human follitropin receptor (hFSHR) and negatively regu-
lated its expression by trapping them in the endoplasmic
reticulum [47-49]. In the monkey CL, the steady state
m R N Al e v e l sf o rF S H Rw e r ee x a m i n e db yb o t hs e m i -
quantitative RT-PCR and qPCR analyses throughout the
luteal phase (Additional file 5: Figure S3). A primer set
exon 11-11(F3-R3) designed outside the region of alter-
native splicing to include all splice variants of the LH/
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Figure 1 Characterization of LH/CGR transcript variants and protein in the monkey CL throughout the luteal phase.( A )C i r c u l a t i n g
mean serum P4 levels and LH/CGR mRNA expression determined during different stages of luteal phase. Individual bars represent mean ± SEM
values (n = 3 animals/stage). For comparison among different stages of luteal phase, one-way ANOVA analysis is performed and bars with
different letters are significantly (p < 0.05) different. (B) Northern blot analysis of LH/CGR mRNA in CL obtained from different stages of the luteal
phase and during regression. Four transcripts of LH/CGR mRNA migrating with apparent sizes of 1.0, 4.0, 7.5 and 8.0 kb are indicated by arrows.
The 28S and 18S ribosomal RNA corresponding to the sizes of 5 kb and 1.86 kb, respectively are also shown. A comparative analysis of LH/CGR
mRNA expression between mid and late stage of luteal phase indicated presence of all four transcripts in the late stage CL. The blots were
reprobed with a
32P labeled L-19 cDNA probe to confirm for equal loading of total RNA. The data shown is for one of three northern blots (n =
3 CL/stage). (C) Semi-quantitative RT-PCR analysis of the LH/CGR mRNA in CL tissues collected during different stages of the luteal phase. In the
upper panel, representative gel pictures of the products obtained after employing two sets of primer pairs designed spanning exon 5-11 and
exon 7-11 regions, respectively. In the lower panel, representative gel pictures of the products obtained employing two sets of primer pairs
designed spanning exon 11 and exon 9 regions, respectively. The positions of amplified products are indicated by arrows. (D) Levels of LH/CGR
protein in the monkey CL throughout the luteal phase. The immunoblot probed with anti-b-actin antibody was utilized to confirm that the
equal amount of protein was loaded in each lane. Densitometric analysis (mean ± SEM) of immunoblots was performed and the protein level in
the mid luteal phase was set as one fold and protein levels in other stages relative to the mid luteal phase are indicated below the respective
bands. (E) Circulating P4 levels before and 2 h after rhLH (20 IU/kg BW) treatment on day 1 of menses. Each bar represents mean ± SEM values
of six independent experiments. Different letters on bars indicate statistical significance (p < 0.05).
Kunal et al. Reproductive Biology and Endocrinology 2012, 10:25
http://www.rbej.com/content/10/1/25
Page 6 of 18CGR and a primer set exon 9-9 (F4-R4) designed within
the exon 9 to examine the expression of exon 9 contain-
ing variant. Semi-quantitative RT-PCR analysis using
these primer sets amplified transcripts throughout the
luteal phase, which followed the pattern of full length
LH/CGR transcript expression (Figure 1C). Immunoblot
analysis of LH/CGR indicated that the protein was pre-
sent throughout the luteal phase including on day 1 of
menses (Figure 1D). To further investigate the function-
ality of LH/CGR present on day 1 of menses, exogenous
administration of rhLH caused significant (p < 0.05)
increase in circulating P4 levels (0.23 ± 0.06 vs. 1.38 ±
0.26 ng/ml at 0 and 2 h post rhLH injection, respec-
tively, Figure 1E).
Expression and characterization of genes belonging to
SFKs and their functional activation in the monkey CL
throughout the luteal phase
Figure 2A shows pictorial representation of various sig-
naling molecules many of which have been identified to
be downstream of LH/CGR activation leading to gene
expression changes. In addition to the well established
canonical pathway and MAP kinase activation pathways,
the likely cross talk between MAP kinase and EGFR
activated SFK’s has been depicted (Figure 2A). The role
of SFKs downstream of LH/CGR activation was exam-
ined in the CL throughout the luteal phase, while the
mRNA expression for Fyn, Yes and Src was present
throughout the luteal phase, expression was higher in
CL collected on day 1 of menses (Figure 2B). The PCR
products of Fyn, Yes and Src were gel eluted, sequenced
and the nucleotide sequences was ≥90% homology to
human and rhesus monkey confirming the presence of
SFKs transcripts in the CL. The expression of Fyn, Yes
and Src was higher (p < 0.05) on day 1 of menses com-
pared to other stages of luteal phase. The activity of Src
k i n a s ei sr e g u l a t e dp o s tt r a n s lationally by phosphoryla-
tion of tyrosine (Y) residues in the catalytic domain i.e.,
phosphorylation at Y-527 would lead to inactivation,
whereas phosphorylation at Y-416 causes full activation.
Immunoblot analysis revealed presence of higher levels
of inactive Src (pSrc Y-527) in early stage CL compared
Figure 2 Expression and characterization of genes belonging to SFKs and their functional activation in the monkey CL throughout the
luteal phase. (A) Diagrammatic representation of various signalling cascades and molecular players involved downstream of LH/CGR activation
regulating various genes associated with steroidogenesis. Based on the review of literature the canonical pathway Gs/cAMP/protein kinase A
(PKA)/pCREB and alternate signalling pathways like p38 MAPK or Erk have been illustrated in the diagram. Furthermore, recent studies describing
involvement of SFKs and cAMP-PDE in modulation of hCG responsiveness and transactivation of tyrosine kinase receptors in mouse Leydig
tumor cells are also represented for their possible similar role in the monkey luteal cells. (B) Semi-quantitative RT-PCR expression of genes
belonging to SFKs (Fyn, Yes and Src) in the monkey CL obtained from different stages of the luteal phase. Each bar represents mean ± SEM
values (n = 3 CL/stage). L-19 mRNA was used as internal control and relative expression was calculated following densitometric analysis. Bars
with different letters indicate statistical significance (p < 0.05). (C) Levels of Src family of kinase protein in the monkey CL throughout the luteal
phase. Immunoblot analysis was performed to determine functional activation of Src protein i.e., protein levels of active pSrc (Y-416), inactive
pSrc (Y-527) and total Src in the monkey CL collected during different stages of the luteal phase. Anti-b-actin antibody (the protein loading
control) probed blot is presented to indicate equal amount of protein being loaded in each lane. Densitometric analysis of immunoblots was
determined and is indicated as mean ± SEM of relative amount of pSrc (Y-416/Y-527) expressed as intensity of total Src/b-actin bands for each
stage of luteal phase (n = 3 CL/stage). Bars with different letters indicate statistical significance (p < 0.05).
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Page 7 of 18to other stages. On the other hand, activated Src (pSrc
Y-416) was high in CL from late and day 1 of menses
compared to CL from early and mid stage of the luteal
phase (Figure 2C).
Expression and characterization of cAMP-PDE (PDE4D)
and its functional activation in the monkey CL during the
luteal phase
To determine the role of PDE, mRNA and protein levels
of an ovarian specific cAMP-PDE (PDE4D) were examined
throughout the luteal phase. The qPCR analysis of PDE4D
mRNA expression was low during early and mid luteal
phase, but the expression was significantly (p < 0.05)
higher at late luteal phase and day 1 of menses compared
to early and mid-luteal phase (Figure 3A). Since, alterna-
tive splicing of the PDE4D mRNA results in generation of
as many as 12 isoforms (PDE4D1-12), isoform specific pri-
mers were designed and semi quantitative RT-PCR analy-
sis for PDE4D3, PDE4D5 and PDE4D6 isoforms was
performed and results showing presence of all isoforms
examined in the CL are presented in Additional file 6: Fig-
ure S4. Immunoblot analysis for PDE4D protein per-
formed utilizing antibody that detects isoform PDE4D 1-6
showed presence of a single PDE4D isoform correspond-
ing to ~70 kDa in the monkey CL, however, all six iso-
forms of PDE4D 1-6 were detected in rat and bovine brain
tissues utilized as positive control (Figure 3B). In the
bovine CL, this anti-PDE4D antibody detected two iso-
forms corresponding to ~70 kDa and ~95 kDa isoforms
whereas, in the rat CL probing with the same antibody
detected a single band corresponding to ~95 kDa (Figure
3B). The PDE4D isoform was detectable throughout the
luteal phase and the results of representative blot are
shown in Figure 3C.
The role of PDE4D depends on its functional activity,
and analysis of cAMP-PDE activity indicated a signifi-
cantly (p < 0.05) higher activity in CL tissue collected
from monkeys on day 1 of menses compared to the mid
stage CL (248.76 ± 26.12 vs. 125.14 ± 32.58 pmol cAMP
hydrolysed/min/mg protein in D1M and MCL, respec-
tively; Figure 3D). Since, LH mediates its action primarily
by activating classical cAMP/PKA/CREB pathway, activa-
tion of SFKs or in turn PDE4D might modulate one of
these components to regulate LH signaling. The PDE4D
hydrolyzes cAMP to 5’AMP and thus play a critical role
in the regulation of intracellular cAMP levels. It was of
interest to examine the cAMP content in CL tissues
throughout the luteal phase. The cAMP content was high
in mid stage compared to CL from late stage and on day
1 of menses and the data is presented in Additional file 7:
Figure S5A, The findings of higher cAMP-PDE activity
together with higher pSrc (Y-416) levels strongly suggest
involvement of SFKs and PDE in modulation of LH
actions leading to loss of function and eventually regres-
sion of CL at the end of non-fertile cycle.
Expression and characterization of LH/CGR and genes
belonging to SFKs in the monkey CL during PGF2a-
induced luteolysis
Expression of LH/CGR and SFKs was examined in the
CL collected during PGF2a-induced luteolysis. Circulat-
ing P4 levels were 3.43 ± 1.06 ng/ml post VEH
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Kunal et al. Reproductive Biology and Endocrinology 2012, 10:25
http://www.rbej.com/content/10/1/25
Page 8 of 18treatment, but after PGF2a treatment the levels were
0.73 ± 0.28 ng/ml at 24 h (Figure 4A). Expression of
LH/CGR mRNA by qPCR analysis showed 4 fold
decrease (p < 0.05) in LH/CGR mRNA in the CL from
PGF2a treated monkeys (Figure 4B). Semi-quantitative
RT-PCR expression analysis indicated increased (p <
0.05) expression of Fyn and Src mRNAs in CL from
PGF2a treated monkeys (Figure4 C ) .T h eL H / C G Rp r o -
tein expression was low (p < 0.05) and activated Src
(pSrc Y-416) expression was high (p < 0.05) in CL tis-
sues collected from PGF2a treated monkeys (Figure 4D).
Expression and characterization of LH/CGR, genes
belonging to SFKs and PDE4D in the CL during LH
secretion inhibition and LH replacement
To examine the effects of LH secretion inhibition and its
subsequent replacement on regulation of SFKs and PDE
activation, monkeys subjected to LH secretion inhibition
by a GnRH receptor antagonist, CET treatment and repla-
cement of LH in CET-treated monkeys were employed.On
day 8 of luteal phase monkeys were administered VEH/
CET and CL was collected at the end of 24 h treatment (n
= 3/VEH or CET treatment) or monkeys were further
treated with PBS or rhLH 24 h post VEH or CET treat-
ment and CL collected at the end of 1 or 8 h PBS/rhLH
treatment. Circulating P4 levels were 3.38 ± 0.35 ng/ml
before CET treatment and decreased significantly to reach
0.58 ± 0.08 ng/ml at 24 h after initiation of CET treatment
(p < 0.05; Figure 5A). Administration of rhLH in CET-
treated monkeys resulted in brisk increase in P4 levels
within 8 h (p < 0.05; Figure 5A). Expression of LH/CGR
mRNA by qPCR analysis indicated ~3 fold decrease post
CET treatment, which did not change (p < 0.05) at 1 and
8 h post LH treatment in CET-treated monkeys (Figure
5B). Immunoblot analysis for LH/CGR protein in CL tis-
sue lysates did not show detectable changes following
CET-induced luteolysis or rescue of CL function by LH
replacement (Figure 5C). The cAMP levels were low post
CET treatment, but increased upon LH replacement
(Additional file 7: Figure S5B). Semi-quantitative RT-PCR
analysis indicated Yes expression was low in CL from
VEH treated monkeys increased (P < 0.05) in CL from 24
h CET and CET + LH (1 h) treated monkeys. Src mRNA
expression was higher after CET and CET + LH treated
monkeys (Figure 5D), while, expression of Fyn was not sta-
tistically significant after CET and LH treatments (Figure
5D). The immunoblot analysis showed higher activated
Src (pSrc Y-416) in CL tissues from CET-treated monkeys,
while LH replacement was able to reverse pSrc (Y-416)
activation (p < 0.05; Figure 5E). The qPCR analysis for
PDE4D mRNA and immunoblot analysis for PDE4D pro-
tein indicated no significant change post CET treatment
or LH replacement (Figure 5F, G).
Expression and characterization of LH/CGR and genes
belonging to SFKs in the monkey CL during simulated
early pregnancy condition
During conception cycles, the function of CL is transi-
ently rescued by the CG secreted from the placental tro-
phoblast. The exogenous administration of incremental
Figure 4 Expression and characterization of LH/CGR and genes belonging to SFKs in the monkey CL during PGF2a-induced luteolysis.
(A) Circulating P4 levels 24 h after VEH/PGF2a treatment. Each bar represents mean ± SEM values (n = 3 animals/treatment). (B) The fold change
in qPCR expression for LH/CGR mRNA in the CL 24 h post VEH/PGF2a treatment. Each bar represents mean ± SEM values (n = 3 animals/
treatment). (C) Semi-quantitative RT-PCR expression of genes belonging to SFKs (Fyn, Yes and Src) in the monkey CL obtained 24 h post VEH/
PGF2a treatment. L-19 mRNA was used as internal control and the relative expression was calculated following densitometric analysis. Each bar
represents mean ± SEM values (n = 3 animals/treatment). (D) Levels of LH/CGR, active pSrc (Y-416) and PDE4D protein in the monkey CL
obtained 24 h post VEH/PGF2a treatment. Anti-b-actin antibody (the protein loading control) probed blot is presented to indicate equal loading
of protein in each lane.
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Page 9 of 18hCG during non fertile cycle to simulate early preg-
nancy has been standardized in the monkey. As can be
seen from Figure 6A, circulating P4 levels increased sig-
nificantly with hCG treatment indicative of increased
CL function (p < 0.05; Figure 6A). However, analysis of
LH/CGR mRNA and protein levels post hCG treatment
did not show a significant change compared to CL from
monkeys not receiving hCG treatment and from day 1
Figure 5 Expression and characterization of LH/CGR, genes belonging to SFKs and PDE4D in the monkey CL following LH secretion
inhibition and LH replacement. (A) Circulating P4 levels following different treatments. Each bar represents mean ± SEM values. For
comparison among various treatment groups, one-way ANOVA analysis was performed and bars with different letters indicate statistical
significance (p < 0.05). (B) The qPCR expression for LH/CGR mRNA in the CL following different treatments. Each bar represents mean ± SEM
values (n = 3 animals/treatment). For comparison among various treatment groups, one-way ANOVA analysis was performed and bars with
different letters indicate statistical significance (p < 0.05). (C) Levels of LH/CGR protein in the monkey CL post CET-induced luteolysis and rescue
of CL function at 1 or 8 h post CET + rhLH treatment. Anti-b-actin antibody (the protein loading control) probed blot is presented to indicate
equal loading of protein in each lane. (D) Semi-quantitative RT-PCR expression of genes belonging to SFKs (Fyn, Yes and Src) in the monkey CL
obtained following different treatments. L-19 mRNA was used as internal control and the fold change in mRNA expression was calculated
following densitometric analysis. Each bar represents mean ± SEM values (n = 3 animals/treatment). For comparison among various treatment
groups, one-way ANOVA analysis was performed and bars with different letters indicate statistical significance (p < 0.05). (E) Immunoblot analysis
was performed to examine functional activation of Src protein i.e., protein levels of active pSrc (Y-416) and total Src in the monkey CL collected
24 h post VEH/CET treatment and at 1 or 8 h post CET + rhLH treatments. Protein lysates (100-200 μg) prepared from CL were resolved on 10%
SDS PAGE, transferred on to PVDF membrane and immunoblot analysis was performed using antibodies raised against pSrc (Y-416), total Src and
total Erk. A representative immunoblot blot for each of the protein antibody probed is shown along with the size of the protein. Anti-Erk
antibody (the protein loading control) probed blot is presented to indicate equal loading of protein in each lane. Densitometric analysis of
immunoblots was determined and the values are indicated as mean ± SEM of relative amount of pSrc (Y-416) expressed as intensity of total Src
bands in each group (n = 3 animals/treatment group). For comparison among various treatment groups, one-way ANOVA analysis was
performed and bars with different letters indicate statistical significance (p < 0.05). (F) The qPCR expression of PDE4D mRNA, in the CL obtained
from monkeys subjected to different treatments. Each bar represents mean ± SEM values (n = 3 animals/treatment). For comparison among
various treatment groups, one-way ANOVA analysis was performed (represented by letter on each bar) and the data across treatment groups
was not significantly different (p > 0.05). (G) Immunoblot analysis was performed to examine PDE4D protein levels in the CL collected from
monkeys subjected to different treatments. A representative immunoblot probed along with anti-b-actin antibody is presented to indicate equal
loading of protein in each lane.
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Page 10 of 18of menses (p > 0.05; Figure 6B). Expression of Fyn, Yes
and Src mRNAs by semi-quantitative RT-PCR analysis
was unaffected (p > 0.05) by hCG treatment, (Figure
6C). However, activated pSrc (Y-416) levels were signifi-
cantly low post hCG treatment compared to levels in
CL from monkeys collected at the late stage and on day
1 of menses (p < 0.05; Figure 6D).
Expression and characterization of genes associated with
steroidogenesis/cholesterol trafficking (HMGR and SR-B1)
and transcription factors (LRH-1 and SF-1) downstream of
LH/CGR signaling
The results from the previous experiments indicated
that the activated SFKs and cAMP-PDE modulate the
molecules downstream of LH/CGR signaling. Another
important aspect of LH/CGR signaling is the regulation
of cholesterol economy of luteal cells for optimal P4 bio-
synthesis and in turn maintenance of CL function. To
examine the role of cholesterol trafficking in the P4 bio-
synthesis some of the molecules that regulate cholesterol
economy of luteal cells were examined by semi-
quantitative RT-PCR and immunoblot analysis. The
mRNA expressions of HMGR, SR-B1, LRH-1 and SF-1
were not significantly (p > 0.05) different at different
stages examined (Figure 7A). The protein levels of SR-
B1 were significantly (p < 0.05) higher in mid stage CL
compared to CL from early and late stage luteal phase
(Figure 7B). In CL of monkeys treated with PGF2a,
mRNA expressions of HMGR and SR-B1 were lower (p
< 0.05) compared to VEH treated monkeys, while
expression of LRH-1 increased and SF-1 expression did
not change (p > 0.05; Figure 7C). Following CET treat-
ment, HMGR expression decreased (p < 0.05) at 24 h
post treatment, remained lower in CL from 1 h LH
treatment monkeys, but recovered in CL of monkeys
that received LH treatment for 8 h (Figure 7D). Expres-
sion of SR-B1 in CL was lower (p < 0.05) 24 h post
CET treatment, but returned to pre CET treatment
levels 8 h after LH replacement (Figure 7D). Changes in
LRH-1 and SF-1 expressions were not seen in CL of
monkeys receiving CET or CET + LH (p > 0.05; Figure
7D). Expression of SR-B1 protein declined 24 h post
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Figure 6 Expression and characterization of LH/CGR and genes belonging to SFKs in the monkey CL during simulated early
pregnancy condition. (A) The graph illustrates circulating mean P4 levels during different days of the luteal phase without (solid circles) and
with hCG (solid triangle) treatment. Each point represents mean ± SEM values (n = 3 animals/control or hCG treatment). Bars with different
letters indicate statistical significance (p < 0.05). (B) The qPCR expression for LH/CGR mRNA (upper panel) and the levels of LH/CGR protein
(lower panel) in the CL from monkeys collected on day 14 without treatment i.e., late CL (L), on day 1 of menses (D1M) and on day 14 following
hCG treatment from day 9-13 of luteal phase (hCG). Each bar in the upper panel represents mean ± SEM values (n = 3 animals/treatment). For
comparison among various groups, one-way ANOVA analysis was performed and the data across groups was not significantly different (p >
0.05). The representative immunoblots probed with anti-LH/CGR antibody and anti-b-actin antibody are shown in the lower panel. Densitometric
analysis (mean ± SEM for n = 3) of immunoblots was performed and the protein levels are indicated below respective bands. L19 mRNA was
used as internal control for qPCR, while b-actin protein level was used as loading control. (C) Semi-quantitative RT-PCR expression of genes
belonging to SFKs (Fyn, Yes and Src) in the CL collected from monkeys on day 14 of luteal phase that received hCG treatment to stimulate early
pregnancy (hCG) or without treatment Late (L). Each bar represents mean ± SEM values (n = 3 animals/control or hCG treatment). L-19 mRNA
was used as internal control and fold change in mRNA expression was calculated following densitometric analysis. (D) Immunoblot analysis was
performed to determine functional activation of Src protein i.e., protein levels of active pSrc (Y-416) and total Src in the CL collected from
monkeys on late luteal phase (L), on day 1 of menses (D1M) and on day 14 of luteal phase following hCG treatment on day 9-13 of luteal phase
(hCG). A representative immunoblot for each of the protein antibody probed is shown along with the size of the protein. Anti-b-actin antibody
(the protein loading control) probed blot is presented to indicate equal loading of protein in each lane. Densitometric analysis of immunoblots
was determined and level of pSrc (Y-416) is expressed as mean ± SEM relative to the intensity of total Src/b-actin. Individual bars with different
letters are significantly different (p < 0.05).
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Page 11 of 18Figure 7 Expression and characterization of genes associated with steroidogenesis/cholesterol trafficking (HMGR and SR-B1) and
transcription factors (LRH-1 and SF-1) downstream of LH-LH/CGR activation. (A) Semi-quantitative RT-PCR expression of mRNA encoded by
HMGR, SR-B1, LRH-1 and SF-1 genes in the CL obtained from monkeys during different stages of the luteal phase (E: early, M: mid, L: late and
D1M: day 1 of menses). Each bar represents mean ± SEM values of three independent experiments. L-19 mRNA was used as internal control and
relative expression was calculated following densitometric analysis. (B) Immunoblot analysis was performed to determine SR-B1 protein levels in
the monkey CL collected during different stages of the luteal phase. A representative immunoblot blot along with blot probed against anti-Erk2
antibody (as protein loading control) is presented. Densitometric analysis of immunoblots was determined and is shown as mean ± SEM of SR-
B1 levels relative to the intensity of Erk2 band in each stage (n = 3 animals/stage). Individual bars with different letters are significantly different
(p < 0.05). (C) Semi-quantitative RT-PCR expression of HMGR, SR-B1, LRH-1 and SF-1 mRNAs in the CL obtained from monkeys 24 h after VEH/
PGF2a treatment. Each bar represents mean ± SEM values of three independent experiments. L-19 mRNA was used as internal control and the
fold change in levels of mRNA for each gene was calculated by densitometric analysis. (D) Semi-quantitative RT-PCR expression of HMGR, SR-B1,
LRH-1 and SF-1 mRNAs in the CL obtained from monkeys post CET-induced luteolysis and rescue of CL function. Each bar represents mean ±
SEM values of three independent experiments. L-19 mRNA was used as internal control and the fold change in levels of mRNA for each gene
was calculated by densitometric analysis. (E) Immunoblot analysis of SR-B1 levels in the CL collected from monkeys post CET-induced luteolysis
and rescue of CL function. A representative immunoblot along with blot probed against anti-Erk2 antibody (as protein loading control) is
presented. Densitometric analysis of immunoblots is shown as mean ± SEM of SR-B1 levels relative to the intensity of Erk2 bands (n = 3 animals/
treatment). Individual bars with different letters are significantly different (p < 0.05). (F) Semi-quantitative RT-PCR expression of HMGR, SR-B1, LRH-
1 and SF-1 mRNAs in the CL collected from monkeys on day 14 of luteal phase without treatment (Late-L) or with hCG treatment to stimulate
early pregnancy (hCG). Each bar represents mean ± SEM values of three independent experiments. L-19 mRNA was used as internal control and
fold change in levels of mRNA for each gene was calculated by densitometric analysis.
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Page 12 of 18CET treatment (p < 0.05; Figure 7E). In CL of monkeys
treated with hCG, mRNA expressions of HMGR, SR-B1,
LRH-1 and SF-1 were not statistically higher (p > 0.05;
Figure 7F).
A model depicting the overall results showing various
molecular players involved downstream of LH/CGR
activation resulting in the regulation of expression of
genes associated with steroidogenesis in the monkey CL
In the monkey CL during mid luteal phase (Figure 8A)
or during rescue of CL function by LH/CG (Figure 8D),
the SFKs or cAMP-PDE activities are kept in check
allowing activation of cAMP/PKA/(pCREB, SF-1/LRH-1)
canonical pathway causing increase in expression of SR-
B1 that results in higher circulating P4.W h e r e a s ,s p o n -
taneous luteolysis (Figure 8B) or induced luteolysis by
PGF2a/CET (Figure 8C) cause withdrawal of inhibition
on activation of SFKs resulting in higher cAMP-PDE
activity leading to attenuation of LH/CG responsiveness,
decrease in SR-B1 expression and lowered circulating P4.
Discussion
In higher primates, the mechanisms responsible for
luteal regression that occurs at the end of non-fertile
cycle are poorly understood. In the present studies,
efforts were made to explain the dichotomy of LH/CG
control of luteal function during non-fertile/fertile cycles
in the monkey. We hypothesized that the signaling path-
ways downstream of LH/CGR may play a crucial role in
modulating the LH/CG actions and in turn CL function.
The results of studies carried out employing various
model systems clearly suggest involvement of SFKs and
cAMP-PDE in the decreased responsiveness of LH/CGR
activated signaling during luteolysis. Furthermore, the
results emphasize the importance of SR-B1, a membrane
receptor protein, for trafficking of cholesterol to be an
F
i
8
Figure 8 A diagrammatic representation of the overall results showing various signalling molecules modulated downstream of LH/
CGR activation regulating genes associated with steroidogenesis during different functional status in the monkey CL. (A) The diagram
describes activation of the well characterized LH-mediated canonical pathway LH/CGR/Gas/AC/cAMP/PKA/(pCREB, SF-1/LRH-1) in the monkey CL,
during mid luteal phase (when the CL function is high) leading to increase in SR-B1 gene expression (both mRNA and protein levels) and in turn
higher serum P4 levels. Further, it also illustrates prevention of SFKs activation and lower cAMP-PDE activity in presence of LH during mid stage
of luteal phase, inturn avoiding modulation of LH/CG responsiveness by the molecular modulators [pSrc (Y-416) and PDE4D]. (B) The diagram
demonstrates decrease in LH-mediated inhibition of SFKs activation and further increase in both SFKs phosphorylation and cAMP-PDE activity in
the monkey CL during spontaneous luteolysis or PGF2a-induced luteolysis (CL function is low) leading to modulation of LH/CG responsiveness in
turn resulting in lower circulating P4 levels. (C) To determine the role of LH in regulation of SFKs activity, LH withdrawal using GnRH-R antagonist
(CET) was performed. The diagram describes the elimination of LH-mediated activation of canonical signalling and increase in both SFKs
phosphorylation and cAMP-PDE activity in the monkey CL during CET-induced luteolysis (CL function is low) leading to decrease in SR-B1 gene
expression and in turn lower circulating P4 levels. (D) To determine the role of LH in regulation of SFKs activity, simulation of early pregnancy
condition was developed and LH replacement in CET treated animals to rescue CL function was performed. The diagram illustrates recurrence of
LH/CG-mediated cAMP/PKA/pCREB signalling and suppression of SFKs activation leading to lower cAMP-PDE activity, higher SR-B1 gene
expression and in turn higher circulating P4 levels.
Kunal et al. Reproductive Biology and Endocrinology 2012, 10:25
http://www.rbej.com/content/10/1/25
Page 13 of 18additional regulatory step influencing steroidogenesis in
luteal cells.
In the present study, LH/CGR expression was
observed to be high at the late luteal phase and the
expression was detectable even on day 1 of menses in
contrast to non detectable expression on day 1 of
menses reported earlier by others [42,50]. Cameron et
al., 1982 [51] reported that the decline in P4 levels seen
during late luteal phase was not accompanied by appre-
ciable decline in number and affinity of LH/CGR. The
results from this study further extend that observation,
since the regressing CL continues to maintain respon-
siveness to exogenous LH/CG stimulation. To rule out
the possibility that the changes in differentially
expressed variants of LH/CGR as previously reported in
the monkey [42], human [52], rat [53] and the bovine
[54], do not contribute to the onset of luteolysis, pre-
sence of multiple splice variants was examined employ-
ing primers designed around the hinge region of LH/
CGR gene. Several studies have reported transcript var-
iants of LH/CGR involving mutations in exon 7 and/or
a b s e n c eo fe x o n1 0l e a d i n gt oloss of receptor expres-
sion to the plasma membrane or loss of LH binding, but
not CG binding to receptor [55-57]. In the present
study, expression of splice variant lacking exon 9 was
characterized and this variant has previously been
reported in humans [46] and rats [58]. Although the
presence of full-length LH/CGR transcript and the
splice variant lacking exon 9 could be established in the
monkey CL, we could not find the differential expres-
sion of these variants as reported for human luteal cells,
in which the truncated variant has been suggested to
modulate the cell surface expression and activity of full-
length LH/CGR [59]. The role of monkey LH/CGR
splice variant lacking exon 9 is not clear, but as reported
previously in human luteal cells, activation of the splice
variant may not lead to increased adenylate cyclise activ-
i t y[ 4 6 ]o rm a yn e g a t i v e l ym o d u l a t ee x p r e s s i o no fw i l d
type gonadotropin receptors by trapping them in the ER
[47-49]. In the monkey, sequestration of gonadotropin
receptors by the exon 9 lacking variant was ruled out
since full length LH/CGR expression was high during
the late luteal phase as shown in Figure 1B, D while the
FSHR expression was low through most part of the
luteal phase as shown in Additional file 5: Figure S3
indicating lack of interaction between LH/CGR tran-
script variant and LH/CGR or FSHR. The findings of
LH/CGR expression and analysis of its transcript var-
iants taken together suggest that the cause for decline in
CL function does not appear to be due to decrease in
LH/CGR expression or changes in expression pattern of
LH/CGR splice variants. Surprisingly, mRNA expression
of LH/CGR post LH inhibition and replacement showed
lower expression but it was not reflected in the changes
in protein levels. One explanation for this discrepancy is
that mRNA levels are low and fluctuating in CL of VEH
treated animals. Also, the antibody employed against
LH/CGR detects one isoform that does not appear
change irrespective of treatments. Moreover, it is possi-
ble that transcriptional changes may not be reflected in
the translational changes at the time points examined.
The review of literature on effects of LH/CG suggests
regulation of various functions of luteal and other steroi-
dogenic cells involve activation of multiple signaling
pathways [14,60,61]. Although LH mediates its action by
Gs/cAMP/PKA/CREB canonical pathway, recently it has
been reported that activation of LH/CGR also results in
activation of other G proteins [11,12] and receptors
involving tyrosine phosphorylation leading to activation
of Ras/ERK1/2 cascade [16,20,21,62,63]. Activation of
ERK cascade may involve other signaling molecules such
as SFKs, b-arrestins, PKA, Ras, Shc and the EGFR as
intermediates in the pathway [64-69]. Studies carried out
employing inhibitors and dominant negative constructs
of SFKs have shown that many of these molecules inter-
act with the canonical LH/CGR activated signaling path-
way resulting in altered responsiveness to steroidogenesis
in ovarian cells [19,70,71], MA-10 tumor Leydig cells
[18,72,73] and adrenal cells [74,75]. In the present study,
expression of genes belonging to SFKs confirm low levels
of activated Src during high steroidogenic state or
increased activated levels of Src during low steroidogenic
state of the CL. The interaction between the LH/CGR
and SFKs can possibly either be a direct [17,76] or indir-
ect involving Pyk2 [77] or b-arrestins [66,78] to keep Src
activation in check. Thus, increased Src activation
observed during low P4 secretion may be due to reduced
responsiveness to LH since cAMP-PDE activity involving
Ras activation may be affected as observed in MA-10 and
ovarian theca cells [18,19,73]. The role of PDE in the reg-
ulation of endocrine cell functions has been well docu-
mented [79-83]. In the present study, presence of few
PDE4D isoforms in the CL tissue also as reported in
other cells was confirmed [84-87]. Initial attempts to cor-
relate increased PDE activity with Src activation was not
successful as it was difficult to determine the direct/indir-
ect interactions in the monkey CL as reported for other
cell types [88-93]. Nonetheless, the results obtained
employing different models systems in the present study
and as hypothesized by other investigators, it can be sug-
gested that modulation of LH/CGR signaling by Src
might involve a role for PDE.
Several studies suggest important role for regulation of
StAR expression by LH in primates [94]. In species such
as bovines, StAR expression appears to be central to
regulation of CL function and further, it may be viewed
that steroidogenesis is critically dependent on factors
that regulate StAR expression [95]. However, the results
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tion by luteal cells involving receptor proteins such as
SR-B1 appears to be also equally important for regula-
tion of CL function in monkeys. SR-B1 mRNA and pro-
tein levels corroborate well with the steroidogenic status
of the CL as reported previously for the ovary [96,97],
adrenal [31,98] and Leydig cells [99,100]. Studies by
others have also suggested that SR-B1 to be a key LH
regulated gene modulating steroidogenic activity as
observed in the present study [27,96]. Moreover, pre-
sence of orphan nuclear transcription factors such as
LRH-1 and SF-1 expression in the monkey CL may sug-
gest transcriptional regulation of SR-B1 expression as
observed in the bovine CL [32]. In summary, based on
the results of the present study, at least four possible
scenarios represented pictorially in Figure 8 can be
thought of to explain the regulation of CL function dur-
ing different functional status. They are: 1) CL during
maximal steroidogenic state (mid luteal phase) and con-
sequently high circulating P4 levels. Upon activation of
Gs/cAMP/PKA/CREB pathway by LH leads to increased
expression of genes such as SR-B1. Further, presence of
the decreased activated pSrc (Tyr-416) level indicates
LH signaling to be inhibitory to Src activation and low-
ered cAMP-PDE activity. 2) CL during spontaneous
luteolysis and/or following PGF2a-induced luteolysis is
concordant with lowered circulating P4 levels. The LH
canonical signaling pathway is modulated by increased
activated pSrc (Tyr-416) levels and cAMP-PDE activity
leading to lowered cAMP levels, PKA activity and
pCREB levels which corroborate well with decreased
expression of SR-B1. 3) CL during decreased luteal func-
tion due to inhibition of circulating LH by CET treat-
ment leading to low circulating P4 levels. The inhibition
of LH canonical signaling pathway leads to increase in
activated pSrc (Tyr-416) levels and cAMP-PDE activity
with concomitant decrease in SR-B1 expression, and 4)
CL during simulated early pregnancy condition and
after LH replacement in the CET-treated monkeys caus-
ing higher or rescued function of CL resulting in higher
circulating P4 levels. The Gs/cAMP/PKA/CREB pathway
is robust with higher cAMP levels, increased PKA activ-
ity and increased pCREB expression consequently
decreased activated pSrc (Tyr-416) and cAMP-PDE
levels, finally leading to higher SR-B1 expression.
Conclusions
The results indicate participation of activated Src [pSrc
(Tyr-416)] and increased activity of cAMP-PDE during
spontaneous luteolysis, while LH/hCG treatment caused
decreased activation of Src and cAMP-PDE activity con-
comitant with increased secretion of P4 in the CL.
Additional material
Additional file 1: Table S1: List of primers employed for semi-
quantitative RT-PCR analysis.
Additional file 2: Table S2: List of primers employed for qPCR
analysis.
Additional file 3: Figure S1: Schematic representation of LH/CGR
gene depicting exons, number of nucleotides in each exon region
and various structural domains formed by each group of exons. The
arrows indicate the multiple primer sets designed around the
alternatively spliced regions to detect various splice variants of LH/CGR
by RT-PCR analysis. The positions of forward primers, F1 and F2 on exon
7 and 5, while position of their respective reverse primers, R1 and R2 on
exon 11 are represented. The positions of two other primer sets (F3-R3
and F4-R4) spanning the extreme 3’ end of exon 11 region and within
the exon 9 region are also represented. The details of splice variants of
LH/CGR reported in literature and the calculated PCR product size for
each of the possible splice variants detected employing multiple primer
sets F1-R1 and F2-R2 in the present study are shown.
Additional file 4: Figure S2: The blast analysis of nucleotide
sequences obtained after sequencing the upper and lower bands
obtained using multiple primer pair set F2-R2 (exon5-11). Shown
here is the multiple sequence alignment of the PCR product sequence
[(A) LH/CGR upper band (718 bp) and (B) lower band (532 bp)]
compared with Gen Bank database sequence of human and monkey
species depicting the sequence identity (*).
Additional file 5: Figure S3: (A) Schematic representation of FSHR
gene depicting exons, various structural domains formed by exons
and number of nucleotides in each exon region. The arrows indicate
the primer set representing position of forward primers (F1&F2) and
reverse primers (R1&R2) designed around the extracellular domain and
hinge regions to detect FSHR mRNA transcripts (sizes 680 and 151 bp).
(B) Semi-quantitative RT-PCR analysis to determine FSHR mRNA
expression in the monkey CL during different stages of the luteal phase
(E: early, M: mid, L: late and D1M: day 1 of menses). L-19 mRNA was
used as internal control and the relative expression was calculated
following densitometric analysis. Each bar represents mean ± SEM values
(n = 3 CL/stage). No significant differences (p > 0.05; denoted by the
same letter on individual bars) in expression was seen throughout the
luteal phase. (C) The qPCR analysis for FSHR mRNA expression in the
monkey CL during different stages of the luteal phase. The fold change
in mRNA expression at each stage CL compared to early stage is
represented in each bar as mean ± SEM values (n = 3 CL/stage). FSHR
expression was high at mid luteal phase, but the expressions at late and
D1M were low. Individual bars with different letters are significantly
different (p < 0.05).
Additional file 6: Figure S4: Semi-quantitative RT-PCR analysis of
PDE4D isoforms [PDE4D3 (A), PDE4D5 (B) and PDE4D6 (C)] was
performed in CL tissue collected from monkeys during different
stages of the luteal phase. The expression of housekeeping gene, L19,
was used as the internal control. Shown here is a representative gel
picture of PDE4D isoforms and L-19 PCR amplification products.
Additional file 7: Figure S5: (A) Tissue cAMP levels in the monkey
CL collected during different stages of the luteal phase. Individual
bars with different letters indicate statistical significance (p < 0.05). (B)
Tissue cAMP levels from animals treated with Vehicle (VEH), CET and CET
+ LH (LH replacement). Individual bars with different letters indicate
statistical significance (p < 0.05).
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